{"filing":{"accession_number":"0001213900-26-065828","cik":"0001766140","ticker":"UNCY","company_name":"Unicycive Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"ea0291976-8k_unicycive.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026065828/ea0291976-8k_unicycive.htm"},"events":[{"id":6548,"run_id":5734,"accession_number":"0001213900-26-065828","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The Company entered into Amendment No. 2 to increase its at-the-market (ATM) offering capacity from $100 million to $150 million in common stock, with a concurrent $50 million shelf registration. ATM offerings are unregistered equity issuances that create dilution risk for existing shareholders and are a material capital-raising event, particularly for smaller biotechnology companies like Unicycive.","company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","filing_date":"2026-06-05","form":"8-K","submitted_at":null,"items":[{"id":4832,"accession_number":"0001213900-26-065828","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company entered into Amendment No. 2 to increase its at-the-market (ATM) offering capacity from $100 million to $150 million in common stock, with a concurrent $50 million shelf registration. ATM offerings are unregistered equity issuances that create dilution risk for existing shareholders and are a material capital-raising event, particularly for smaller biotechnology companies like Unicycive.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:21:08.422112+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4832,"accession_number":"0001213900-26-065828","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company entered into Amendment No. 2 to increase its at-the-market (ATM) offering capacity from $100 million to $150 million in common stock, with a concurrent $50 million shelf registration. ATM offerings are unregistered equity issuances that create dilution risk for existing shareholders and are a material capital-raising event, particularly for smaller biotechnology companies like Unicycive.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:21:08.422112+00:00","company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","filing_date":"2026-06-05"}]}